Iktos
Alexis Denis has a diverse work experience in the pharmaceutical and biopharmaceutical industry. Alexis started their career at Aventis in 1989, where they worked as a Group Leader in the Medicinal Chemistry Department. During their time at Aventis, they managed two Medicinal Chemistry laboratories and led a multi-disciplinary antibacterial project. Alexis also played a role in project management and had compounds in various phases of development.
In 2002, Alexis moved to Pfizer, where they served as an Associate Director of the Medicinal Chemistry Department in France. In this position, they co-directed a chemistry department and managed a team of scientists. Alexis was responsible for supervising projects in the allergy and respiratory diseases area and played a role in budgeting, alliances, and collaborations.
From 2004 to 2008, Alexis worked at Mutabilis as the VP and Director of Medicinal Chemistry. Alexis headed the Medicinal Chemistry and Lead Optimization division and had shared responsibilities for drug discovery strategies, outsourcing, partnerships, and alliances. Additionally, they were involved in corporate and business development and managed the company.
In 2008, Alexis joined GSK, where they held two director-level positions. As the Director of Candidate Discovery, they supported drug discovery activities across GSK R&D and was a member of the Leadership Team of the Research Center. Alexis also had responsibilities for scientific and drug discovery strategies, partnerships, alliances, and collaborations.
Alexis then worked at Oncodesign as the Director of Medicinal Chemistry from 2016 to 2020. In this role, they oversaw medicinal chemistry and played a part in drug discovery strategies, outsourcing, partnerships, and alliances.
Most recently, Alexis joined Galapagos in 2020 as the Head of Late Medicinal Chemistry. In this position, they led late medicinal chemistry activities until they made a transition to their current role as the SVP and Head of Drug Discovery at Iktos in 2023.
Overall, Alexis Denis has extensive experience in various aspects of drug discovery and medicinal chemistry, with a focus on leadership, strategic planning, and partnerships.
Alexis Denis has a PhD in Organic Chemistry, with a focus on Medicinal Chemistry. They obtained their PhD from Pierre and Marie Curie University, with their education spanning from an unspecified start year to an unspecified end year. Additionally, they completed another PhD in Organic Chemistry from the same university, which started in 1979 and concluded in 1986.
This person is not in any offices
Iktos
Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.